Can patients with invasive ductal carcinoma that is estrogen‑receptor positive, progesterone‑receptor positive, and HER2‑negative have a Mirena (levonorgestrel‑releasing intrauterine system) inserted?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 1, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Mirena IUS is Generally Contraindicated in Patients with ER/PR-Positive Breast Cancer

Patients with invasive ductal carcinoma that is ER/PR-positive and HER2-negative should NOT have a Mirena (levonorgestrel-releasing intrauterine system) inserted, as hormone replacement therapy and progestin exposure increase the risk of breast cancer recurrence.

Rationale Based on Guidelines

The ESMO guidelines explicitly state that "the use of hormone replacement therapy increases the risk of recurrence and should be discouraged" in breast cancer survivors 1. This recommendation applies to all forms of exogenous hormone exposure, including progestin-containing devices like the Mirena IUS.

For patients on tamoxifen (which many ER/PR-positive breast cancer patients receive), guidelines recommend annual gynecological examination to monitor for endometrial effects 1. The addition of a levonorgestrel-releasing device would complicate this surveillance and potentially interfere with endocrine therapy efficacy.

Evidence from Research Studies

The research evidence demonstrates concerning associations between LNG-IUS use and breast cancer risk:

  • A Finnish nationwide cohort study found that LNG-IUS users had an increased risk for both ductal breast cancer (SIR 1.20) and lobular breast cancer (SIR 1.33) compared to the general population 2
  • The highest risk was observed in women who used the device long-term (purchased at least twice), with a SIR of 1.73 for lobular cancer 2
  • Another Finnish study showed LNG-IUS users had a 19% higher incidence of breast cancer than expected (SIR 1.19) 3

While one meta-analysis suggested no increased risk 4, the individual cohort studies with larger sample sizes and longer follow-up consistently demonstrate elevated breast cancer risk, particularly for hormone receptor-positive disease.

Clinical Implications

For a patient with established ER/PR-positive invasive ductal carcinoma:

  • The tumor has already demonstrated hormone sensitivity by expressing estrogen and progesterone receptors
  • Systemic progestin exposure from the LNG-IUS could potentially stimulate residual disease or micrometastases
  • The patient likely requires adjuvant endocrine therapy (tamoxifen or aromatase inhibitors), and adding progestin exposure is counterproductive to this treatment strategy

Alternative Contraceptive Options

If contraception is needed, consider:

  • Copper IUD (ParaGard) - non-hormonal option that provides effective long-acting contraception without progestin exposure 5
  • Barrier methods - condoms, diaphragm
  • Permanent sterilization - if family planning is complete

Common Pitfall to Avoid

Do not assume that local progestin delivery from an IUS has negligible systemic effects. While the LNG-IUS releases lower doses than oral progestins, systemic absorption does occur and has been associated with increased breast cancer risk in population studies 3, 2. The local-versus-systemic distinction does not eliminate the contraindication in hormone-sensitive breast cancer.

References

5
Guideline

contraception for adolescents.

Pediatrics, 2014

Related Questions

What is the recommended management for a 42‑year‑old woman with left‑sided breast carcinoma staged as T4b N2 M0 and a triple‑negative core needle (trucut) biopsy?
What adjuvant therapy is recommended for a 45-year-old premenopausal woman with an 18 mm grade 1 hormone‑receptor‑positive HER2‑negative invasive ductal carcinoma and negative sentinel nodes after lumpectomy?
In a 56-year-old postmenopausal woman with invasive ductal carcinoma that is estrogen receptor (ER) and progesterone receptor (PR) positive, HER2 negative, who has completed adjuvant chemotherapy and mastectomy, what is the next recommended treatment?
In a 57-year-old woman with menopausal estradiol ~50 pg/mL, follicle‑stimulating hormone ~9.6 IU/L, random vaginal spotting, hot flashes, night sweats, and a levonorgestrel intrauterine device (Liletta), what diagnostic work‑up is indicated?
What is the best treatment option for a 33‑year‑old G3P2 woman with stage III invasive breast cancer that is HER2‑positive and estrogen‑ and progesterone‑receptor negative, who is 13 weeks pregnant (first trimester) and not in labor?
In a pediatric patient with atrial fibrillation, should aspirin or warfarin be used for stroke prevention?
Given a CT scan showing no acute abdominal or pelvic abnormality, a microlith in the right kidney, a stable small right renal cortical cyst, a stable simple hepatic cyst, status post cholecystectomy, atheromatous mural calcification of the abdominal aorta and its branches, and lumbar spondylosis with no significant interval change, what is the appropriate management?
Which blood test can directly confirm lymphoma?
When should debridement of a wound be performed in an elderly patient?
Is ultrasound (US) superior to computed tomography (CT) for assessing fatty liver?
In a pregnant patient with a TSH of 4.14 mIU/L who is taking 125 µg levothyroxine, should the levothyroxine dose be increased?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.